Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Income towards Parent Company: 2022-2024

Historic Income towards Parent Company for Addex Therapeutics (ADXN) over the last 3 years, with Dec 2024 value amounting to $13.6 million.

  • Addex Therapeutics' Income towards Parent Company rose 65.69% to -$892,300 in Q2 2025 from the same period last year, while for Jun 2025 it was -$1.6 million, marking a year-over-year increase of 79.94%. This contributed to the annual value of $13.6 million for FY2024, which is 251.63% up from last year.
  • Latest data reveals that Addex Therapeutics reported Income towards Parent Company of $13.6 million as of FY2024, which was up 251.63% from -$9.0 million recorded in FY2023.
  • In the past 5 years, Addex Therapeutics' Income towards Parent Company ranged from a high of $13.6 million in FY2024 and a low of -$10.5 million during FY2022.
  • Its 3-year average for Income towards Parent Company is -$2.0 million, with a median of -$9.0 million in 2023.
  • Data for Addex Therapeutics' Income towards Parent Company shows a peak YoY skyrocketed of 251.63% (in 2024) over the last 5 years.
  • Addex Therapeutics' Income towards Parent Company (Yearly) stood at -$10.5 million in 2022, then increased by 14.43% to -$9.0 million in 2023, then skyrocketed by 251.63% to $13.6 million in 2024.